


## Hederagenin

<b>Cat. No.:</b>	HY-N0256		
<b>CAS No.:</b>	465-99-6		
<b>Molecular Formula:</b>	C <sub>30</sub> H <sub>48</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	472.7		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (105.78 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.1155 mL	10.5775 mL	21.1551 mL
		5 mM	0.4231 mL	2.1155 mL	4.2310 mL
10 mM		0.2116 mL	1.0578 mL	2.1155 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>Hederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κB. Hederagenin can exhibit multiple pharmacological activities in the treatment of hyperlipidemia, antilipid peroxidation, antiplatelet aggregation, liver protection, antidepressant, anti-inflammation. [1] In vitro: 1) Hederagenin can correct the imbalance of endothelial function by inhibiting the release of large amounts of iNOS and increasing eNOS contents and inhibits the IKKβ/NF-κB signaling pathway to reduce the release of IL-6, IFN-γ, TNF-α, and other inflammatory factors. [1] 2) The EC<sub>50</sub> of hederagenin is 39 ± 6 μM in A549 cancer cell line, but it's inactive for DLD-1 cells. [2] 3) Hederagenin inhibited LPS-induced production of NO, PGE<sub>2</sub> and cytokines in cells. [3] 4) Hederagenin had an anti-edema effect on the CA-induced mouse hind paw edema assay. [3] 5) Hederagenin inhibited the CA-induced increase in skin thicknesses. [3] In vivo: The rats in the hederagenin group were administered hederagenin at 20 mg/kg/d via gavage. (More details please refer to the protocol below). In AS rat models induced by a high-lipid diet plus VD3, hederagenin can effectively reduce serum lipid, ALT, and AST</p>
--------------------	--

---

levels, in addition to improving liver function, relieving high blood coagulation, and slowing blood flow and stasis by improving blood rheology. [1]

---

## REFERENCES

---

- [1]. Su-Hong Lu et al. Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats. *Evid Based Complement Alternat Med*, 2015, Oct 19
- [2]. Diego Rodríguez-Hernández et al. Hederagenin as a triterpene template for the development of new antitumor compounds. *Eur J Med Chem*, 2015 Nov 13, 105:57-62
- [3]. Chul Won Lee et al. Hederagenin, a major component of *Clematis mandshurica* Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice. *Int Immunopharmacol*, 2015 Dec, 29(2):528-37.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA